SCHEMBL30177201

SCHEMBL30177201

COCCCn1cc2ccccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 3/20 0.43
FLT3 P36888 1/20 0.43
MPO P05164 1/20 0.41
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 5/20 0.40
HPGD P15428 5/20 0.40
GAA P10253 4/20 0.40
HSD17B10 Q99714 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
GLA P06280 3/20 0.40
HTT P42858 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
TSHR P16473 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28237663 0.90 MPO (0.46) IRAK4MPOALDH1A1KDM4EHPGD
SCHEMBL18073162 0.81 TLR8 (0.55) MPOGAASMN1; SMN2TLR8TLR7
SCHEMBL254046 0.80 TLR8 (0.50) MPOALDH1A1HTTTLR8TLR7
SCHEMBL17981711 0.80 DUT (0.43) IRAK4FLT3ALDH1A1SMN1; SMN2HTT
SCHEMBL3074994 0.79 IRAK4 (0.44) IRAK4FLT3ALDH1A1KDM4EHSD17B10
SCHEMBL29311541 0.79 TLR8 (0.49) MPOSMN1; SMN2TLR8TLR7MAPT
SCHEMBL9229133 0.79 TLR8 (0.49) MPOSMN1; SMN2TLR8TLR7MAPT
SCHEMBL17981794 0.78 PDE4D (0.42) IRAK4MPOALDH1A1KDM4EHPGD
SCHEMBL9038635 0.78 SLC9A1 (0.44) ALDH1A1SMN1; SMN2TLR8TLR7MAPT
SCHEMBL3078992 0.78 IRAK4 (0.41) IRAK4FLT3MPOALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002361-A1 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002361-A1 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK3, IRAK2 IRAK4 1/4885FLT3 64/4885MPO 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.